News from ucb A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 25, 2019, 07:00 ET UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers

– Regulated information – Revenue reached € 2.3 billion (+2%, +4% CER1) net sales increased to € 2.2 billion (+3%, +5% CER – adjusted2 +11%, +7% CER) ...


Mar 02, 2019, 07:00 ET Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

UCB, a global biopharmaceutical company, presented positive data from the Phase 2b BE ABLE extension study of bimekizumab in patients with...


Feb 28, 2019, 13:55 ET UCB Full Year Report 2018: 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's Strong Pipeline

"We are confident for the future growth of UCB based on strong delivery in 2018, marking the fifth year of profitable growth in a row and a new...


Nov 30, 2018, 08:00 ET UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership

UCB is excited to be presenting 20 abstracts at this year's American Epilepsy Society Meeting, taking place between November 30 and December 4 in New ...


Oct 30, 2018, 05:00 ET UCB First Nine Months Interim Report 2018: UCB tracking well towards full year financial outlook

"We are pleased with UCB's performance in the first nine months of 2018, which is in-line with our financial outlook for 2018. Since June, we are...


Oct 18, 2018, 07:00 ET UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful...


Oct 18, 2018, 00:01 ET The Impact of Fragility Fractures due to Osteoporosis is Being Ignored

New survey reveals that 61 per cent of women over 60 have little or no knowledge of osteoporosis,[1] despite the fact that one in three is likely to...


Jul 11, 2018, 08:00 ET UCB Launches the Autoimmune Motherhood (AIM) Movement™ to Empower and Inform Women with Chronic Inflammatory Disease About Family Planning

UCB, a global biopharmaceutical company, today announced the launch of the Autoimmune Motherhood (AIM) Movement to support women living with chronic...


Jul 02, 2018, 12:30 ET UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease

NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without...


Jun 15, 2018, 01:00 ET New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey

UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatment and research, today presents findings from a patient...


May 29, 2018, 08:00 ET UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.

The U.S. Food and Drug Administration's (FDA) approval of CIMZIA® (certolizumab pegol) for use in moderate-to-severe plaque psoriasis marks the entry ...


May 16, 2018, 04:02 ET CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

Positive top line results from Phase 3 C-AXSPAND study underscore the potential of CIMZIA® (certolizumab pegol) for non-radiographic axial...


May 14, 2018, 08:00 ET UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients

- BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with...


Apr 05, 2018, 07:00 ET UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off

UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). The...


Mar 22, 2018, 08:00 ET CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

U.S. Food and Drug Administration (FDA) approves label change for UCB's CIMZIA® (certolizumab pegol) Data added to the label includes...


Feb 16, 2018, 10:08 ET UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018)

UCB, a global biopharmaceutical company, will be presenting new data on CIMZIA® (certolizumab pegol) and one of UCB's key pipeline molecules,...


Jan 09, 2018, 01:00 ET CIMZIA® (certolizumab pegol) Label Change Marks Important Advance for European Women of Childbearing Age With Chronic Rheumatic Disease

European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in...


Nov 06, 2017, 08:00 ET UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting

Key data focus on inflammatory and osteoporosis in patient populations with unmet needs including women of childbearing age and others: The results...


Nov 06, 2017, 07:00 ET UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients

VIMPAT® (lacosamide) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with...


Sep 15, 2017, 01:00 ET New indication for BRIVIACT® (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for BRIVIACT®...


Jun 13, 2017, 18:01 ET Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy

UCB today presented results from CRIB, a pharmacokinetic study designed to assess if CIMZIA® (certolizumab pegol) is transferred across the placenta...


Apr 21, 2017, 12:30 ET UCB showcases latest epilepsy research at 2017 Annual Meeting of the American Academy of Neurology

UCB is pleased to announce that 12 scientific abstracts have been accepted for presentation at the upcoming Annual Meeting of the American Academy of ...


Mar 15, 2017, 07:00 ET UCB Launches Wellness 4U, an Innovative and Comprehensive Health and Wellness Program for Patients with Immunologic Diseases

UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatments and research, has launched Wellness 4U™, an...


Mar 06, 2017, 00:00 ET First CIMZIA® (certolizumab pegol) Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk

Today UCB announced results from the CRADLE study, the first lactation study designed to evaluate CIMZIA® (certolizumab pegol) concentrations in...


Jan 19, 2017, 11:00 ET UCB files BRIVIACT® (brivaracetam) CV in the U.S. as monotherapy treatment for adult epilepsy patients with partial-onset seizures

UCB has today announced the filing of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for BRIVIACT®...